Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...